EP. 1: Adopting Neoadjuvant Therapy into Ovarian Cancer
EP. 2: HIPEC in Advanced Ovarian Cancer
EP. 3: Upfront Bevacizumab in Advanced Ovarian Cancer
EP. 4: Incorporating Bevacizumab into First-Line Practice for EOC
EP. 5: Bevacizumab in the Neoadjuvant Setting of EOC
EP. 6: Maintenance Therapy in Ovarian Cancer: PARP Inhibitors
EP. 7: I-O Therapy in Advanced Ovarian Cancer
EP. 8: Biomarkers and Molecular Testing in Ovarian Cancer
EP. 9: Approaching Recurrent Ovarian Cancer
EP. 10: Bevacizumab in Recurrent Ovarian Cancer
EP. 11: Secondary Debulking in Recurrent Ovarian Cancer
EP. 12: PARP Inhibitors in Recurrent Ovarian Cancer
EP. 13: Additional Considerations: PARPs for EOC in Practice
EP. 14: PARP Inhibitor Selection in Ovarian Cancer
EP. 15: Sequencing Therapies in Ovarian Cancer
EP. 16: Therapy Selection in BRCA-Mutated Ovarian Cancer
EP. 17: Managing Ovarian Cancer Patients in the Future
Oncology Experts Preview Top Abstracts From 2025 ASCO GU
Dr Somaiah on Ongoing Research With Novel Agents in Sarcomas
Dr Hamid on the Potential for Cancer Vaccines in Melanoma
Dr Orloff on Treatment Strategies for Rapidly Progressing Uveal Melanoma